GLP-1 Agonists Explained: Ozempic®/ Wegovy® (Semaglutide) vs. Mounjaro®/Zepbound™ (Tirzepatide)
1. Why GLP-1s Are Having a Moment Glucagon-like peptide-1 (GLP-1) receptor agonists lower appetite, slow gastric emptying, and boost insulin. Novo Nordisk’s Ozempic®/Wegovy® (semaglutide) mimics GLP-1 alone, while Lilly’s Mounjaro®/Zepbound™ (tirzepatide) hits both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, making it a “dual incretin.” That extra target may explain its headline-grabbing results. (Wikipedia) 2.…












